Avenue TherapeuticsATXI
13F holders, Q3 2024 (September 30)8holders −1
1new positions
1sold out
$2.49avg. 13F price*
At the end of Q3 2024, 8 institutions reported holding Avenue Therapeutics Inc. (ATXI) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($286K), Sabby Management, LLC ($157K) and Moss Adams Wealth Advisors LLC ($27K).
- Company
- Avenue Therapeutics Inc.
- CUSIP
- 05360L403
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $27K |
| Exits | 1 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 82,639 shares bought and 1,473 shares sold, net +81,166 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Armistice Capital, LLC | 0.01% | Add +53.3% | 115,000 | $286K |
| Sabby Management, LLC | 2.18% | Add +68.6% | 63,060 | $157K |
| Moss Adams Wealth Advisors LLC | 0.00% | New | 11,000 | $27K |
| UBS Group AG | 0.00% | Add +812.8% | 6,143 | $15K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -45.7% | 1,740 | $4K |
| Wells Fargo & Company | 0.00% | Add +819.7% | 561 | $1K |
| Bank of America Corp. | 0.00% | Add +42.9% | 10 | $25 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is ATXI's weight in each manager's 13F, not the share of Avenue Therapeutics Inc. the manager owns.